This post, longer than most (apologies), reflects take-aways from a one-hour zoom program reflecting thinking at the annual January San Francisco conference on medtech held under JP Morgan auspices. That zoom was sponsored by MassBio and I am told it was recorded and will be made available; below is my summary and omits some discussion and is intended to be suggestive and not definitive. Speakers included an investment banker, two attorneys and one medtech in-house counsel.
- Is 2026 going to be a good year? Some optimism but no one predicts a boom in funding or M&A (perhaps exits?). Pessimism in 2025 was based on politics, tariffs, US economy generally, international events; perhaps those factors are today better understood and perhaps players are more willing to deal, but those concerns continue to some degree. Some areas seem poised to be strong (see below) and one new development is seeming willingness of lenders to support strong emerging companies with non-equity (debt) funding. Much emphasis on importance of having companies seeking funding or M&A getting their houses in order as diligence will be intense: do you have right people, do you know your market, are you offering something that moves a needle rather than being a modest increment, do you understand applicable reimbursement, do you have strong financial projections.
- The future is much about applying AI to bio and medtech. Strong view that the future is NOW. Companies that will succeed will be applying AI to process and product fully, and not on a trial balloon, testing basis. Do players have a plan to integrate AI and have the staff that can use it fully now? AI as part of the “service offering is a requisite.” Further, AI in health care will result in operational efficiency so the lack of staffing today will be eased as doctors and care givers are relieved of many tasks and are able to focus on application of medicine. Finally, note Open AI and Anthropics have released recent advances in AI to improve medtech, telling you the AI community is active in positioning in medtech.
- Beware mid-term elections. Emphasis is on doing deals before mid-terms, which likely will affect many factors regardless of which party wins and will take time to assess in terms of investment, market and M&A.
- Tariffs had some impact on planning in 2025 and less impact on markets; they remain a question, caused movement of manufacture and supply chains onshore. Remain a factor in an unknown environment.
- Improved health does not reduce need for medicine, procedures, etc; rather as people get healthier they live longer, need more, increase need for procedures. A major factor that is not yet fully understood is the effect of progress in weight loss. Rough example: someone weighs 500 pounds, dies or if survives has no incentive to improve body to be functional and live longer; someone down to 200 pounds wants to replace the knee, fix the shoulder, attend to medication more assiduously, etc.
- Acknowledging mixed view of prospects for 2026, what areas are thought to be most promising for funding, M&A? Cardio, women’s health (with one dissent from the sole female panelist), surgical visualization, ortho, robotic surgery (as use of machines is adopted by more and smaller hospitals). But nothing “frothy” is to be expected; these are measured predictions.